External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>gAdvair and gAbraxane are expected to contribute to revenue growth in FY25E, as regulatory challenges ease.</li><li>gSynbicort has been filed, and one peptide product, valued at $300-400 Mn, has already been launched, with plans to introduce two more peptides in FY25E.</li><li>Cipla has demonstrated success in launching peptides over the past year. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

gAdvair and gAbraxane are expected to contribute to revenue growth in FY25E, as regulatory challenges ease.gSynbicort has been filed, and one peptide product, valued at $300-400 Mn, has already been launched, with plans to introduce two more peptides in FY25E.Cipla has demonstrated success in launching peptides over the past year. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

CIPLA Ltd - Strong Gross Margins Led by Healthy Product Mix

Cipla Ltd

CIPLA Ltd - Strong Gross Margins Led by Healthy Product Mix